2021
Diagnostic renal mass biopsy is associated with individual categories of PADUA and RENAL nephrometry scores: Analysis of diagnostic and concordance rates with surgical resection
Fonseca RB, Straub Hogan MM, Kapp ME, Cate F, Coogan A, Arora S, Gordetsky J, Smelser WW, Clark PE, Cates J, Giannico GA. Diagnostic renal mass biopsy is associated with individual categories of PADUA and RENAL nephrometry scores: Analysis of diagnostic and concordance rates with surgical resection. Urologic Oncology Seminars And Original Investigations 2021, 39: 371.e7-371.e15. PMID: 33773915, PMCID: PMC8205938, DOI: 10.1016/j.urolonc.2021.02.022.Peer-Reviewed Original ResearchConceptsCore needle biopsySmall renal massesFine-needle aspirationRenal mass biopsyDiagnostic core needle biopsyDiagnostic fine needle aspirationRenal massesNon-diagnostic rateCystic massMass biopsyConcordance rateEndophytic growthRenal sinus invasionRENAL nephrometry scoreSurgical resection specimensSurgical resectionNephrometry scoreSinus invasionRetrospective studyPreoperative aspectsResection specimensSingle institutionClinical managementSubset analysisNeedle biopsy
2020
Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer.
Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Fütterer J, Serrallach M, Relle J, Lotan Y, Heidenreich A, Bonekamp D, Haider M, Tirkes T, Arora S, Macura KJ, Costa DN, Persigehl T, Pantuck AJ, Bomers J, Burtnyk M, Staruch R, Eggener S. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. Journal Of Urology 2020, 205: 769-779. PMID: 33021440, DOI: 10.1097/ju.0000000000001362.Peer-Reviewed Original ResearchConceptsGrade Group 2 diseaseProstate-specific antigen reductionGrade group 2Whole gland ablationTransurethral ultrasound ablationAntigen reductionMagnetic resonance imagingProstate cancerGroup 2Gland ablationMagnetic resonance imaging-guided transurethral ultrasound ablationGrade 3 adverse eventsResonance imagingTarget volumeEvidence of cancerUltrasound ablationIntermediate-risk diseaseRisk prostate cancerProspective multicenter trialMedian prostate volumeLocalized prostate cancerMedian treatment delivery timeTreatment delivery timeMagnetic resonancePrimary endpointVariability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel
Westphalen AC, McCulloch CE, Anaokar JM, Arora S, Barashi NS, Barentsz JO, Bathala TK, Bittencourt LK, Booker MT, Braxton VG, Carroll PR, Casalino DD, Chang SD, Coakley FV, Dhatt R, Eberhardt SC, Foster BR, Froemming AT, Fütterer JJ, Ganeshan DM, Gertner MR, Mankowski Gettle L, Ghai S, Gupta RT, Hahn ME, Houshyar R, Kim C, Kim CK, Lall C, Margolis DJA, McRae SE, Oto A, Parsons RB, Patel NU, Pinto PA, Polascik TJ, Spilseth B, Starcevich JB, Tammisetti VS, Taneja SS, Turkbey B, Verma S, Ward JF, Warlick CA, Weinberger AR, Yu J, Zagoria RJ, Rosenkrantz AB. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology 2020, 296: 76-84. PMID: 32315265, PMCID: PMC7373346, DOI: 10.1148/radiol.2020190646.Peer-Reviewed Original ResearchConceptsPositive predictive valuePI-RADS scoreProstate cancerPI-RADSGleason scorePredictive valueRetrospective cross-sectional studyHigh-grade prostate cancerObserved positive predictive valueOverall positive predictive valueUntreated prostate cancerProstate MRIInterquartile rangeSignificant prostate cancerProstate Imaging ReportingCross-sectional studyMixed-model logistic regressionProstate cancer diseaseReporting Data SystemMRI lesionsBiopsy resultsActive surveillanceClinical careMRI scansImaging ReportingMagnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer: Preliminary Experience from a Single Center in a Prospective, Multi-Center, Single-Arm Clinical Trial
Sundaram KM, Staruch R, Burtnyk M, Lane JS, Penson DF, Arora SS. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer: Preliminary Experience from a Single Center in a Prospective, Multi-Center, Single-Arm Clinical Trial. Journal Of Vascular And Interventional Radiology 2020, 31: 740-746.e4. PMID: 32307311, DOI: 10.1016/j.jvir.2019.12.802.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAgedAged, 80 and overHumansMagnetic Resonance Imaging, InterventionalMaleMiddle AgedNeoplasm GradingNeoplasm StagingOntarioPreliminary DataProspective StudiesProstatic NeoplasmsTime FactorsTransurethral Resection of ProstateTreatment OutcomeUltrasonic Surgical ProceduresConceptsTransurethral ultrasound ablationProstate cancerMagnetic resonance imaging-guided transurethral ultrasound ablationIntermediate-risk prostate cancerUltrasound ablationIntermediate-risk diseaseSingle-center experienceGastrointestinal side effectsLocalized prostate cancerArm clinical trialMagnetic resonance imagingHistologic benefitPostprocedural changesPrimary endpointSingle centerClinical trialsMulti-CenterSide effectsPreliminary experienceResonance imagingPatientsProstate treatmentCancerAblationBiopsy